指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

肝硬化患者接受上消化道内镜与腹腔穿刺术的凝血病管理:多学科德尔菲法中的持续差距与共识领域

Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
指南 / 共识 · Hepatology · 2024-04-01
一句话结论多学科德尔菲共识提出:诊断性腹腔穿刺及诊断性内镜无需查INR、应避免血浆输注;门诊诊断性操作预防性输血小板风险大于获益;连续阿司匹林可用于各项操作。

该研究采用改良德尔菲法(3轮评分),由11名具备内容专长的专家组成小组,成员包括介入放射学、输血医学和麻醉学专业学会提名者,以及血液学、急诊医学、移植外科和社区实践的代表,旨在为肝硬化患者腹腔穿刺和上消化道内镜围操作期凝血病管理建立共识性过程指标。从286项候选指标中最终确定33项。共识包括:诊断性或治疗性腹腔穿刺及诊断性内镜无需检测国际标准化比值(INR);所有腹腔穿刺和诊断性内镜应避免血浆输注;门诊诊断性腹腔穿刺和诊断性内镜预防性输血小板风险大于获益;其他操作在血小板计数>20,000/mm³时风险大于获益;连续阿司匹林对每项操作均允许。治疗性或急诊内镜及是否停用全身抗凝未达成共识。

要点

  • 诊断性或治疗性腹腔穿刺以及诊断性内镜无需检测INR。
  • 所有腹腔穿刺和诊断性内镜应避免血浆输注。
  • 门诊诊断性腹腔穿刺和诊断性内镜预防性输血小板风险大于获益。
  • 其他操作在血小板计数>20,000/mm³时,预防性输血小板风险大于获益。
  • 连续阿司匹林对每项操作均允许;氯吡格雷对诊断性和治疗性腹腔穿刺及诊断性内镜允许。

适用人群与场景

  • 接受上消化道内镜或腹腔穿刺的肝硬化患者。
  • 共识涉及门诊诊断性腹腔穿刺、诊断性内镜、治疗性腹腔穿刺、治疗性内镜和急诊内镜等场景。

诊断标准与关键阈值

  • 以改良德尔菲法(3轮评分)达成共识,最终从286项候选指标中确定33项过程指标。
  • 血小板计数>20,000/mm³时,其他操作(除门诊诊断性腹腔穿刺和诊断性内镜外)预防性输血小板的风险大于获益;低于20,000/mm³时其他场景下风险是否大于获益尚不确定。

处置流程与药物剂量

  • 诊断性或治疗性腹腔穿刺以及诊断性内镜无需检测INR。
  • 所有腹腔穿刺和诊断性内镜应避免血浆输注。
  • 门诊诊断性腹腔穿刺和诊断性内镜应避免预防性输血小板(风险大于获益)。
  • 其他操作在血小板计数>20,000/mm³时应避免预防性输血小板(风险大于获益)。
  • 连续阿司匹林对每项操作均允许。
  • 氯吡格雷对诊断性和治疗性腹腔穿刺及诊断性内镜允许。

研究设计与关键结果

  • 研究为改良德尔菲法共识,11名专家小组,3轮评分,从286项候选指标中最终确定33项过程指标。
  • 诊断性或治疗性腹腔穿刺及诊断性内镜无需检测INR;所有腹腔穿刺和诊断性内镜应避免血浆输注。
  • 门诊诊断性腹腔穿刺和诊断性内镜预防性输血小板风险大于获益;其他操作在血小板计数>20,000/mm³时风险大于获益;低于20,000/mm³时其他场景下风险是否大于获益尚不确定。
  • 治疗性或急诊内镜的INR检测和血浆输注未达成共识;是否继续或停用全身抗凝未达成共识。
  • 连续阿司匹林对每项操作均允许;氯吡格雷对诊断性和治疗性腹腔穿刺及诊断性内镜允许。

证据类型、等级与局限

  • 证据类型:多学科改良德尔菲法共识(3轮评分)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些共识领域可作为肝硬化围操作期凝血病管理的一套共同实践指标的基础。
  • 对诊断性腹腔穿刺和诊断性内镜,可不检测INR,避免血浆输注,门诊诊断性操作避免预防性输血小板。
  • 其他操作在血小板计数>20,000/mm³时避免预防性输血小板;低于20,000/mm³时其他场景下风险是否大于获益尚不确定。
  • 连续阿司匹林对每项操作均允许;氯吡格雷对诊断性和治疗性腹腔穿刺及诊断性内镜允许。
  • 治疗性或急诊内镜的INR检测和血浆输注、是否继续或停用全身抗凝尚无共识。

指南或共识出处

  • Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi(Hepatology)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Patients with cirrhosis have abnormal coagulation indices such as a high international normalized ratio and low platelet count, but these do not correlate well with periprocedural bleeding risk. We sought to develop a consensus among the multiple stakeholders in cirrhosis care to inform process measures that can help improve the quality of the periprocedural management of coagulopathy in cirrhosis. We identified candidate process measures for periprocedural coagulopathy management in multiple contexts relating to the performance of paracentesis and upper endoscopy. An 11-member panel with content expertise was convened. It included nominees from professional societies for interventional radiology, transfusion medicine, and anesthesia as well as representatives from hematology, emergency medicine, transplant surgery, and community practice. Each measure was evaluated for agreement using a modified Delphi approach (3 rounds of rating) to define the final set of measures. Out of 286 possible measures, 33 measures made the final set. International normalized ratio testing was not required for diagnostic or therapeutic paracentesis as well as diagnostic endoscopy. Plasma transfusion should be avoided for all paracenteses and diagnostic endoscopy. No consensus was achieved for these items in therapeutic intent or emergent endoscopy. The risks of prophylactic platelet transfusions exceed their benefits for outpatient diagnostic paracentesis and diagnostic endosopies. For the other procedures examined, the risks outweigh benefits when platelet count is >20,000/mm 3 . It is uncertain whether risks outweigh benefits below 20,000/mm 3 in other contexts. No consensus was achieved on whether it was permissible to continue or stop systemic anticoagulation. Continuous aspirin was permissible for each procedure. Clopidogrel was permissible for diagnostic and therapeutic paracentesis and diagnostic endoscopy. We found many areas of consensus that may serve as a foundation for a common set of practice metrics for the periprocedural management of coagulopathy in cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

参考来源

  1. Tapper EB, Warner MA, Shah RP, et al. Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology. 2024. PMID: 38557474. doi:10.1097/HEP.0000000000000856

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。